Ruxolitinib phosphate

CAS No:
1092939-17-7

Molecular Formula：

C17H21N6O4P

Molecular Weight：

404.36

Storage:

Store at -20℃

Synonyms:

Ruxolitinib monophosphate
(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate (1:1)
436LRU32H5
CHEBI:66917
25127112
MFCD18452860

IUPAC Name:

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; phosphoric acid

InChIKey:

JFMWPOCYMYGEDM-XFULWGLBSA-N

InChI:

InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1

SMILES:

C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O

Download Product Documents

Missing docs? Contact support.

Ruxolitinib-phosphate-cas-1092939-17-7-COA

Request a Quote

Technical Data

Appearance	White to off-white or light pink powder
Solubility	Highly soluble in water, and the solubility is pH dependant.
Identification	IR: The IR absorption spectrum of the sample must be concordant with Test Standard HPLC: The retention time of the major peak in the chromatogram conforms to the characteristic peak of R.S.
Melting Point	194℃~198℃
pH	2.0~3.0
Water Content	Not more than 1.0%
Enantiomer	≤1.0%
Related Substances	Any other impurity: Not more than 0.5% Total impurities: Not more than 1.0
Assay (on anhydrous basis)	98.0%~102.0%

Description

Ruxolitinib is an oral JAK1/2 inhibitor with potential antineoplastic and immunomodulating activities, targeting JAK-STAT pathways implicated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Safety Information

GHS

Pictogram:

GHS07 GHS08 GHS06

Signal Word:

Danger

Hazard Statements:

H301 (66.7%): Toxic if swallowed [Danger Acute toxicity, oral]
H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]
H361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H373 (66.7%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
H412 (33.3%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

Precautionary Statements:

P203 – Obtain, read and follow all safety instructions before use.
P260 – Do not breathe dust/fume/gas/mist/vapours/spray.
P264 – Wash thoroughly after handling.
P270 – Do not eat, drink or smoke when using this product.
P273 – Avoid release to the environment.
P280 – Wear protective gloves/protective clothing/eye protection/face protection.
P301+P316 – IF SWALLOWED: Get emergency medical help immediately.
P301+P317 – IF SWALLOWED: Get medical help.
P318 – If exposed or concerned, get medical advice.
P319 – Get medical help if you feel unwell.
P330 – Rinse mouth.
P405 – Store locked up.
P501 – Dispose of contents/container to in accordance with local/regional/national/international regulations.

References

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.

[2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31.

[3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631.

Q & A / Review

Reviews

There are no reviews yet.

Be the first to review “Ruxolitinib phosphate”